<DOC>
	<DOCNO>NCT00002780</DOCNO>
	<brief_summary>RATIONALE : Biological therapy use different way stimulate immune system stop cancer cell grow . Combining different type biological therapy may kill tumor cell . PURPOSE : Phase I/II trial study effectiveness T cell interleukin-2 combined peripheral stem cell transplantation bone marrow transplantation treat woman stage IIIB metastatic breast cancer .</brief_summary>
	<brief_title>Biological Therapy Treating Women With Metastatic Breast Cancer</brief_title>
	<detailed_description>OBJECTIVES : I . Evaluate toxicity combination low dose interleukin-2 ( IL-2 ) sargramostim ( GM-CSF ) , multiple dos activate T cell ( ATC ) follow peripheral blood stem cell transplantation woman stage IIIB metastatic adenocarcinoma breast . II . Evaluate efficacy regimen patient . OUTLINE : Patients receive filgrastim ( G-CSF ) subcutaneously daily 5 day prior peripheral blood stem cell ( PBSC ) collection 2 day prior bone marrow harvest . Following PBSC collection bone marrow harvest , patient receive high dose chemotherapy consist cyclophosphamide IV , carboplatin IV , thiotepa IV day -6 -3 . Patients undergo PBSC transplantation day 0 . Following PBSC transplantation , patient receive multiple dos monoclonal antibody OKT3 activate T lymphocytes IV 1 hour day 1 65 , continuous low dose interleukin-2 ( IL-2 ) IV day 1-65 , sargramostim ( GM-CSF ) subcutaneously day 5-21 . Patients follow day 100 , clinically indicate , annually . PROJECTED ACCRUAL : Approximately 40-60 patient accrue study within 1-2 year .</detailed_description>
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Cyclophosphamide</mesh_term>
	<mesh_term>Thiotepa</mesh_term>
	<mesh_term>Aldesleukin</mesh_term>
	<mesh_term>Carboplatin</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically document metastatic adenocarcinoma breast Concurrent intraductal lobular carcinoma situ allow Bilateral disease allow Measurable evaluable recurrent metastatic disease ( Stage IIIB IV ) document radiograph , CT scan , nuclear medicine scan , physical exam Tumor must clinically chemosensitive documented reduction tumor burden No clinical evidence brain metastasis PATIENT CHARACTERISTICS : Age : 18 Performance status : Karnofsky 70100 % Life expectancy : Not specify Hematopoietic : Granulocyte count least 1,500/mm3 Platelet count least 50,000/mm3 Hemoglobin least 8 g/dL Hepatic : Bilirubin le 1.5 time normal Hepatitis B surface antigen negative Renal : Creatinine le 1.8 mg/dL Creatinine clearance normal Blood urea nitrogen ( BUN ) less 1.5 time normal Cardiovascular : Ejection fraction least 45 % MUGA No uncontrolled significant cardiovascular disease include myocardial infarction ( less 1 year ) congestive heart failure Pulmonary : PFTFEV1 least 60 % predict DLCO FVC least 60 % predict Other : Not pregnant Negative pregnancy test HIV negative No serious medical psychiatric illness No prior concurrent malignancy , curatively treat carcinoma situ cervix basal cell skin cancer PRIOR CONCURRENT THERAPY : See Disease Characteristics No concurrent hormonal therapy breast cancer</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2001</verification_date>
	<keyword>stage IV breast cancer</keyword>
	<keyword>recurrent breast cancer</keyword>
	<keyword>stage IIIB breast cancer</keyword>
</DOC>